Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SAVA Cassava Sciences Inc

Post-Market Trading 01-08 19:32:30 EST

2.83

-0.19

-6.46%

盘后2.86

+0.03+1.22%

19:26 EST

High3.00	Low2.70	Vol3.64M
Open2.92	D1 Closing3.02	Amplitude9.93%
Mkt Cap135.91M	Tradable Cap122.25M	Total Shares48.11M
T/O10.23M	T/O Rate8.40%	Tradable Shares43.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SAVA","market":"US","secType":"STK","nameCN":"Cassava Sciences Inc","latestPrice":2.825,"timestamp":1736370000000,"preClose":3.02,"halted":0,"volume":3635102,"hourTrading":{"tag":"盘后","latestPrice":2.8594,"preClose":2.825,"latestTime":"19:26 EST","volume":23045,"amount":65282.691793,"timestamp":1736382367843},"delay":0,"floatShares":43274073,"shares":48110475,"eps":-1.37344,"marketStatus":"Post-Market Trading","change":-0.195,"latestTime":"01-08 19:32:30 EST","open":2.92,"high":3,"low":2.7,"amount":10228531.797395,"amplitude":0.099338,"askPrice":2.87,"askSize":1,"bidPrice":2.81,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.37344,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1736384400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.02,"preHourTrading":{"tag":"盘前","latestPrice":2.9494,"preClose":3.02,"latestTime":"09:29 EST","volume":88870,"amount":262597.475065,"timestamp":1736346553973},"postHourTrading":{"tag":"盘后","latestPrice":2.8594,"preClose":2.825,"latestTime":"19:26 EST","volume":23045,"amount":65282.691793,"timestamp":1736382367843},"volumeRatio":0.727649,"optionData":{"bulkOrders":[{"symbol":"SAVA","call":true,"expireDate":1740114000000,"strike":"3.0","timestamp":1736361656435,"price":0.3,"volume":3000,"amount":90000,"type":"-"}]},"impliedVol":1.2297,"impliedVolPercentile":0.4802},"requestUrl":"/m/hq/s/SAVA/wiki","defaultTab":"wiki","newsList":[{"id":"2501747302","title":"Cassava Sciences to Reduce Staff, Halt Further Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2501747302","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501747302?lang=en_us&edition=fundamental","pubTime":"2025-01-08 19:09","pubTimestamp":1736334591,"startTime":"0","endTime":"0","summary":"Cassava Sciences  said late Tuesday that it is reducing its workforce by ten employees, laying off 33% of its workforce in Q1, incurring one-time expenses of $400,000 for the reduction.The clinical-stage company said it will reduce expenses by halting the planned biomarker analysis of additional plasma samples from previous mid-stage studies of its investigational potential treatments for central nervous system diseases including Alzheimer's disease.The measures come after the company said a late-stage study of its drug simufilam as a potential treatment for Alzheimer's patients did not meet its endpoints.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4547","BK4585","SAVA","BK4007","BK4588"],"gpt_icon":0},{"id":"2501759217","title":"BRIEF-Cassava Sciences Provides A Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2501759217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501759217?lang=en_us&edition=fundamental","pubTime":"2025-01-08 06:49","pubTimestamp":1736290179,"startTime":"0","endTime":"0","summary":"BRIEF-Cassava Sciences Provides A Business UpdateJan 7 (Reuters) - Cassava Sciences Inc SAVA.O:CASSAVA SCIENCES PROVIDES A BUSINESS UPDATECASSAVA SCIENCES INC: IMPLEMENTING COST CURTAILMENT INCLUDING ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA4QCJDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","SAVA","BK4585","BK4547"],"gpt_icon":0},{"id":"2501758928","title":"Cassava Sciences Inc: in Final Stages of Discontinuing Refocus-Alz Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2501758928","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501758928?lang=en_us&edition=fundamental","pubTime":"2025-01-08 05:30","pubTimestamp":1736285400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA4QCJDC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SAVA","BK4585","BK4007","BK4588","BK4547"],"gpt_icon":0},{"id":"2501758926","title":"Cassava Sciences Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2501758926","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501758926?lang=en_us&edition=fundamental","pubTime":"2025-01-08 05:30","pubTimestamp":1736285400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA4QCJDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4007","SAVA","BK4588","BK4547"],"gpt_icon":0},{"id":"2501758188","title":"Cassava- Topline Data From Phase 3 Refocus-Alz Study of Simufilam in Patients With Mild-to-Moderate Alzheimer's Disease Expected Late Q1/Early Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501758188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501758188?lang=en_us&edition=fundamental","pubTime":"2025-01-08 05:30","pubTimestamp":1736285400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA4QCJDC:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","SAVA","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2501589257","title":"Cassava Sciences Inc: Implementing Cost Curtailment Including a Workforce Reduction of Approximately 33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501589257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501589257?lang=en_us&edition=fundamental","pubTime":"2025-01-08 05:30","pubTimestamp":1736285400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA4QCJDC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4547","BK4007","SAVA","BK4588"],"gpt_icon":0},{"id":"2501475826","title":"Cassava Sciences Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2501475826","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501475826?lang=en_us&edition=fundamental","pubTime":"2025-01-08 05:30","pubTimestamp":1736285400,"startTime":"0","endTime":"0","summary":"Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment inclu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005863/8339/en/Cassava-Sciences-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PET","PHH","BK4547","BK4192","BK4601","BK4585","ETH","SAVA","BK4007"],"gpt_icon":0},{"id":"2491779357","title":"Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky LLP","url":"https://stock-news.laohu8.com/highlight/detail?id=2491779357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491779357?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:50","pubTimestamp":1734040204,"startTime":"0","endTime":"0","summary":"THE LAWSUIT: A class action securities lawsuit was filed against Cassava Sciences, Inc. (SAVA) that seeks to recover losses of Cassava Sciences, In...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/lost-money-on-cassava-sciences-inc-sava-join-class-action-suit-seeking-recovery-contact-levi-korsinsky-llp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/lost-money-on-cassava-sciences-inc-sava-join-class-action-suit-seeking-recovery-contact-levi-korsinsky-llp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SAVA","BK4585","BK4588","BK4007","BK4547"],"gpt_icon":0},{"id":"2487592243","title":"Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2487592243","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487592243?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:51","pubTimestamp":1732906260,"startTime":"0","endTime":"0","summary":"Pipeline and regulatory updates are in focus in the biotech sector. Among these, BridgeBio Pharma, Inc. BBIO gained on approval of cardiovascular drug while a few others faced setbacks.BridgeBio Pharma, Inc. announced that it has obtained FDA approval for its pipeline candidate acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy  to reduce cardiovascular death and cardiovascular-related hospitalization. The candidate has been approved under the brand name Attruby. BBIO stock surged on the news.The FDA approval is based on positive results from the phase III ATTRibute-CM study, in which Attruby significantly reduced death and cardiovascular-related hospitalization and improved quality of life. The approval came ahead of the targeted action date of Nov. 29.MariTide caused approximately 20% average weight loss over 52 weeks without reaching a weight loss plateau. In patients with type II diabetes who were obese or overweight, the weight loss reduction was ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-bbio-stock-185100614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AMGN","BK4566","SAVA","LU0889565916.HKD","LU2112291526.USD","BK4585","LU0058720904.USD","IE00BJJMRZ35.SGD","BK4533","LU1023059063.AUD","SG9999001440.SGD","BK4599","BK4581","LU1057294990.SGD","IE0009355771.USD","BK4505","BK4547","LU0320765992.SGD","SAVAW","BBIO","LU0122379950.USD","LU1983299246.USD","BK4139","LU1061106388.HKD","IE00B2B36J28.USD","BK4534","IE00B4R5TH58.HKD","LU0109394709.USD","BK4588","APLT","BK4007","LU0289739699.SGD","LU0868494617.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU1571399168.USD","LU2242652126.USD","LU2242646821.SGD"],"gpt_icon":1},{"id":"2486844322","title":"Cassava Sciences: Probably The End Of The Saga","url":"https://stock-news.laohu8.com/highlight/detail?id=2486844322","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486844322?lang=en_us&edition=fundamental","pubTime":"2024-11-27 18:37","pubTimestamp":1732703833,"startTime":"0","endTime":"0","summary":"Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation of all ongoing trials.With no other drug candidates in the pipeline, the company's prospects are bleak.I believe the stock may end up trading below the company's last-reported cash position of $149 million.   Pakin Jarerndee  Thesis On November 25, 2024, Cassava Sciences  has announced topline data of the first of two blinded, randomized placebo-controlled Phase 3 trials for the treatment of mild and moderate Alzheimer’s disease. The results were disappointing for investors. Cassava","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2083966639/image_2083966639.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2083966639/image_2083966639.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4740592-cassava-sciences-probably-the-end-of-the-saga","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SAVA","BK4588","BK4547","BK4585","BK4007"],"gpt_icon":1},{"id":"2486856869","title":"A Post-Mortem on Cassava Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2486856869","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486856869?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:36","pubTimestamp":1732656960,"startTime":"0","endTime":"0","summary":"There are few things in the investment world scarier than owning a biotech that misses the mark. That was the case this morning with once high-flying stock Cassava Sciences . This is a stock that once skyrocketed to $146. A little over three years later, this thing closed the day at $4.30, down 83% on the day.It’s Alzheimer’s drug Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in its Phase 3 study. The good news, if there is any, is that Cassava still has $149 million in cash as of the end of last quarter. The bad news is, they’ve got a strikeout where they were hoping to hit a home run.Moving Averages: Bartosiak starts by examining the stock's moving averages, such as the 50-day and 200-day moving averages. He points out the significance of crossovers and divergences between these averages, which can indicate potential trend changes.To read this article on Zacks.com click here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/post-mortem-cassava-sciences-213600264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","SAVA","POST","SAVAW","BK4007","BK4547","BK4212","BK4588"],"gpt_icon":1},{"id":"2486857065","title":"Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin","url":"https://stock-news.laohu8.com/highlight/detail?id=2486857065","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486857065?lang=en_us&edition=fundamental","pubTime":"2024-11-27 04:30","pubTimestamp":1732653034,"startTime":"0","endTime":"0","summary":"Cassava Sciences' Alzheimer's drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials.SAVA stock ","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2021145941/image_2021145941.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2021145941/image_2021145941.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4740470-cassava-sciences-phase-3-alzheimers-drug-fail-final-nail-in-coffin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4547","SAVA","BK4588","BK4007","BK4585"],"gpt_icon":1},{"id":"2486835124","title":"SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2486835124","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486835124?lang=en_us&edition=fundamental","pubTime":"2024-11-27 02:42","pubTimestamp":1732646520,"startTime":"0","endTime":"0","summary":"Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study for Alzheimer’s disease .SAVA releases top-line results from the ReThink-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive or functional decline in AD patients when compared to placebo over a 52-week period, as assessed by the ADAS-COG12 and ADCS-ADL scales. The study failed to meet any pre-specified secondary and exploratory biomarker endpoints.Based on the above study results, Cassava also decided to discontinue the phase III ReFocus-ALZ study, which evaluated simufilam in AD patients over a 76-week period. It will also be discontinuing the open-label extension study on the drug.In a related action, the SEC charged Dr. Hoau-Yan Wang, a consultant for Cassava and associate medical professor a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sava-stock-plunges-84-alzheimers-184200032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B2B36J28.USD","LU0256863902.USD","LU0320765059.SGD","BIIB","LU1868836591.USD","LU2237438978.USD","LU2237443549.SGD","LU2361044949.HKD","LU1974910355.USD","LLY","LU0094547139.USD","SG9999014880.SGD","LU2602419157.SGD","SAVA","LU0708995401.HKD","BK4533","LU2324357040.USD","LU2360106947.USD","LU0106261372.USD","LU0198837287.USD","IE00BJT1NW94.SGD","LU0114720955.EUR","SSI","LU1023059063.AUD","LU1917777945.USD","IE00BJJMRZ35.SGD","BK4139","LU1804176565.USD","LU1093756168.USD","LU0354030511.USD","LU0820561909.HKD","LU0203202063.USD","LU0385154629.USD","LU2023250504.SGD","SAVAW","LU0006306889.USD","IE0004445239.USD","LU1623119135.USD","BK4547","BK4599","LU0689472784.USD","LU1712237335.SGD","BK4532","LU0289739699.SGD","LU0061475181.USD","LU2264538146.SGD","BK4516","LU0471298694.HKD","LU1551013342.USD","LU2468319806.SGD","LU2106854487.HKD"],"gpt_icon":1},{"id":"2486882439","title":"What’s left in Cassava after Phase 3 setback for Alzheimer’s drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2486882439","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486882439?lang=en_us&edition=fundamental","pubTime":"2024-11-27 00:17","pubTimestamp":1732637842,"startTime":"0","endTime":"0","summary":"Eoneren/E+ via Getty ImagesCassava Sciences  crashed nearly 84% following a late-stage trial setback for its lead asset, simufilam, leaving SAVA investors wondering what’s in store for the once-high-flying biotech after its dramatic fall from grace on Monday. The Austin, Texas-based biotech, which commanded more","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2180760614/image_2180760614.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2180760614/image_2180760614.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4335916-whats-cassava-stock-post-alzheimers-setback","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SAVA","BK4588","BK4547","BK4585","BK4007"],"gpt_icon":0},{"id":"2486009708","title":"Cassava Sciences Shares Fall 4% After 84% Slump in Previous Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2486009708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486009708?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:40","pubTimestamp":1732632003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nFWN3MX0QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4007","SAVA","BK4585","BK4547"],"gpt_icon":0},{"id":"1164696232","title":"Stock Track | Cassava Sciences Stock Plunges 5.47% on Analyst Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1164696232","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164696232?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:35","pubTimestamp":1732631706,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc  stock plummeted 5.47% in pre-market trading on Tuesday, following an analyst downgrade by H.C. Wainwright.H.C. Wainwright analyst Vernon Bernardino lowered the rating on Cassava Sciences from Buy to Neutral, removing the price target on the stock. The downgrade came after the company announced a disappointing development related to its Alzheimer's drug candidate.The analyst action weighed heavily on investor sentiment, triggering a selloff in Cassava Sciences shares during ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"623fca2674be5d59cafa190844bb8df5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SAVA"],"gpt_icon":1},{"id":"2486888431","title":"Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2486888431","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486888431?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:35","pubTimestamp":1732631702,"startTime":"0","endTime":"0","summary":"A downtrend has been apparent in Cassava Sciences, Inc.  lately with too much selling pressure. The stock has declined 83.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index , one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.To read this article on Zacks.com click here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ksLAzii1aL14haHFbPC1Rg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ksLAzii1aL14haHFbPC1Rg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/down-83-93-4-weeks-143502592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","SAVAW","BK4588","RSI","BK4007","BK4547","BK4150","SAVA"],"gpt_icon":1},{"id":"2486710570","title":"HC Wainwright Downgrades Cassava Sciences to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2486710570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486710570?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:24","pubTimestamp":1732623843,"startTime":"0","endTime":"0","summary":"HC Wainwright Downgrades Cassava Sciences to Neutral From Buy","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"623fca2674be5d59cafa190844bb8df5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SAVA"],"gpt_icon":0},{"id":"2486076327","title":"Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Tuesday; Cassava Sciences to Advance, MicroStrategy to Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2486076327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486076327?lang=en_us&edition=fundamental","pubTime":"2024-11-26 19:45","pubTimestamp":1732621534,"startTime":"0","endTime":"0","summary":"The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Tuesday's opening bell.Cassava Sciences (SAVA) was up 1.5% in premarket hours, swinging from an 83.8% plunge ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSLA","LU1280957306.USD","MSTR","MSTR.AU","IE00BQXX3C00.GBP","LU2357305700.SGD","NVDU","IE00B19Z9505.USD","LU1242518931.SGD","BK4529","LU1988902786.USD","LU2491050071.SGD","NVD2.UK","LU0889565833.HKD","MARA","NVDA","LU1974910355.USD","SAVA","RKLB","LU2756315664.SGD","LU0957791311.USD","2NVD.UK","SNVD.UK","LU0642271901.SGD","LU0057025933.USD","LU0267386448.USD","LU0345768153.USD","LU2505996509.AUD","SMCI","3NVD.UK","NVD3.UK","ACHR","NVDS.UK","LU1571399168.USD","LU2237957902.USD","NVDD","NVDY","SG9999015945.SGD","LU2326559502.SGD","NVD","LU0077335932.USD","NVDX","LU0724617625.USD","NVDS","LU1267930730.SGD","IE00BKDWB100.SGD","BK4516"],"gpt_icon":1},{"id":"2486073411","title":"Cassava Sciences downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2486073411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486073411?lang=en_us&edition=fundamental","pubTime":"2024-11-26 19:17","pubTimestamp":1732619820,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company announced...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cassava-sciences-downgraded-to-neutral-from-buy-at-h-c-wainwright-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":"623fca2674be5d59cafa190844bb8df5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cassava-sciences-downgraded-to-neutral-from-buy-at-h-c-wainwright-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4007","BK4547","SAVA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cassavasciences.com","stockEarnings":[{"period":"1week","weight":0.2797},{"period":"1month","weight":-0.0621},{"period":"3month","weight":-0.8792},{"period":"6month","weight":-0.7252},{"period":"1year","weight":-0.8756},{"period":"ytd","weight":0.2797}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0578},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.56,"avgChangeRate":0.16039},{"month":2,"riseRate":0.416667,"avgChangeRate":0.028198},{"month":3,"riseRate":0.458333,"avgChangeRate":0.024377},{"month":4,"riseRate":0.583333,"avgChangeRate":0.060573},{"month":5,"riseRate":0.416667,"avgChangeRate":0.028089},{"month":6,"riseRate":0.458333,"avgChangeRate":-0.016342},{"month":7,"riseRate":0.458333,"avgChangeRate":0.000768},{"month":8,"riseRate":0.48,"avgChangeRate":0.013502},{"month":9,"riseRate":0.6,"avgChangeRate":0.108222},{"month":10,"riseRate":0.4,"avgChangeRate":-0.045759},{"month":11,"riseRate":0.6,"avgChangeRate":-0.00953},{"month":12,"riseRate":0.36,"avgChangeRate":0.032425}],"exchange":"NASDAQ","name":"Cassava Sciences Inc","nameEN":"Cassava Sciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cassava Sciences Inc,SAVA,Cassava Sciences Inc股票,Cassava Sciences Inc股票老虎,Cassava Sciences Inc股票老虎国际,Cassava Sciences Inc行情,Cassava Sciences Inc股票行情,Cassava Sciences Inc股价,Cassava Sciences Inc股市,Cassava Sciences Inc股票价格,Cassava Sciences Inc股票交易,Cassava Sciences Inc股票购买,Cassava Sciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction